6:47 PM
 | 
Feb 04, 2009
 |  BC Extra  |  Top Story

FDA panel split on ecallantide

FDA's Pulmonary-Allergy Drugs Advisory Committee sent mixed signals about Kalbitor ecallantide ( DX-88) from Dyax (NASDAQ:DYAX), voting 6-5 with two abstentions that the company has provided evidence to support approval of the yeast-derived recombinant plasma

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >